Small Cell Lung Carcinoma: all 1,234 studies
Page 8 of 13. Open to participants first (350), then studies with results posted, then the rest; newest registration first within each.
- A Phase Ib / IIA Study of AL8326 in Small Cell Lung CancerStatus unknownNCT04890795Phase 1/2
- A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung CancerStatus unknownNCT04884009Phase 2
- Concurrent Chemoradiotherapy Combination With Anlotinib for Limited-stage Small Cell Lung CancerStatus unknownNCT04882033Phase 1
- A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLCCompletedNCT04878016Phase 3
- A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung CancerTerminatedNCT04870112Phase 1
- IMFINZI Study in Patients With Extensive Stage Small Cell Lung CancerCompletedNCT04854590
- A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic TumorsWithdrawnNCT04841538Phase 1/2
- A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)CompletedNCT04834778Phase 1
- Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung CancerCompletedNCT04830813Phase 3
- The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)CompletedNCT04818983
- Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking AbilityActive, not recruitingNCT04804644Phase 3
- Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing TumorsActive, not recruitingNCT04802876Phase 2
- Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine CancersActive, not recruitingNCT04802174Phase 1/2
- Effect of Combination Therapy on SCLC After Initial Treatment FailureStatus unknownNCT04790955
- a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung CancerStatus unknownNCT04790539Phase 2
- Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung CancerStatus unknownNCT04782089Not applicable
- A Single-arm, Phase Ⅱ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung CancerStatus unknownNCT04757779Phase 2
- Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid TumorsCompletedNCT04742959Phase 1/2
- Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung CancerStatus unknownNCT04740021Phase 2
- Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung CancerStatus unknownNCT04731909Not applicable
- Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung CancerCompletedNCT04730999Phase 2
- Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC)CompletedNCT04727853Phase 2
- Impact of Low Muscle Mass in HNC Treated With ImmunotherapyStatus unknownNCT04721184
- TH1902 in Patients With Advanced Solid TumorsActive, not recruitingNCT04706962Phase 1
- Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine CarcinomasActive, not recruitingNCT04701307Phase 2
- Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st ChemotherapyStatus unknownNCT04698941Phase 2
- Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer PatientsStatus unknownNCT04696939Phase 2
- Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung CancerStatus unknownNCT04684017Phase 2
- Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLCStatus unknownNCT04683198Phase 2
- Anlotinib Plus Platinum-etoposide in First-line of Extensive-stage Small-cell Lung CancerStatus unknownNCT04675697Phase 2
- A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above ChemotherapiesCompletedNCT04672928Phase 1
- A Real-world Study of Durvalumab for Lung Cancer in ChinaStatus unknownNCT04672759
- Real World Study of Efficacy and Safety of Atezolizumab Plus Chemotherapy in Chinese Patients With ES-SCLCStatus unknownNCT04663438
- CAR-macrophages for the Treatment of HER2 Overexpressing Solid TumorsActive, not recruitingNCT04660929Phase 1
- Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung CancerCompletedNCT04660097Phase 2
- A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）Status unknownNCT04659785Phase 1/2
- A Trial of SHR-1316 Maintenance Therapy for Limited Stage Small Cell Lung CancerStatus unknownNCT04647357Phase 2
- Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With TumorsCompletedNCT04640480Phase 1
- A Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)CompletedNCT04636762Phase 2
- Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)Active, not recruitingNCT04624204Phase 3
- Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung CancerCompletedNCT04622228Phase 2
- Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line ChemotherapyStatus unknownNCT04620837Phase 2
- Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLCTerminatedNCT04610658Phase 1
- TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell TherapyTerminatedNCT04596033Phase 1
- SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLCActive, not recruitingNCT04562337Phase 2
- PF-07104091 as a Single Agent and in Combination TherapyActive, not recruitingNCT04553133Phase 2
- Venetoclax and Irinotecan in Relapsed/Refractory SCLCWithdrawnNCT04543916Phase 1/2
- PCI for Patients With ES-SCLC After RCT:a Prospective Randomized StudyStatus unknownNCT04535739Phase 3
- AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung CancerTerminatedNCT04525391Phase 2
- Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain MetastasisActive, not recruitingNCT04516070Phase 2
- Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung CancerNo longer availableNCT04507919
- First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid TumoursCompletedNCT04504669Phase 1
- Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung CancerApproved for marketingNCT04504513
- Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)CompletedNCT04501497
- A Study of Gimatecan (ST1481) in Small Cell Lung CancerStatus unknownNCT04501029Phase 2
- Simultaneous Integrated Boost vs. Routine IMRT in Limited-stage Small-cell Lung CancerStatus unknownNCT04500145Phase 3
- Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer.Status unknownNCT04490421Phase 3
- Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung CancerCompletedNCT04487756Phase 1/2
- Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).Active, not recruitingNCT04472949Phase 2
- A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)Active, not recruitingNCT04471727Phase 1/2
- Thoracic RadiothErapy with Atezolizumab in Small Cell LUng CanceR Extensive DiseaseCompletedNCT04462276Phase 2
- Study of PF-07265807 in Participants With Metastatic Solid Tumors.TerminatedNCT04458259Phase 1
- A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）Status unknownNCT04453930Phase 2
- Effect of Hyponatremia in Small Cell Lung CancerCompletedNCT04451460
- The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to SurveillanceActive, not recruitingNCT04450043Not applicable
- Feasibility of Wearable Activity Trackers for Detection of TOXicity in People Receiving Systemic Anticancer TreatmentStatus unknownNCT04440800
- IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung CancerCompletedNCT04434482Phase 1/2
- A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3Active, not recruitingNCT04429087Phase 1
- Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC PatientsCompletedNCT04421352Phase 1
- A Study of SYHA1807 in Subjects With Extensive-Stage Small Cell Lung CancerStatus unknownNCT04404543Phase 1
- A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung CancerCompletedNCT04400188Phase 1/2
- Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung CancerActive, not recruitingNCT04397003Phase 2
- Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung CancerCompletedNCT04381910Phase 2
- First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLCStatus unknownNCT04363255Phase 2
- Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer SubjectsCompletedNCT04361825Phase 2
- Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.CompletedNCT04358237Phase 1/2
- A Study of PLM60 in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First-Line ChemotherapyTerminatedNCT04352413Phase 2
- Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung CancerStatus unknownNCT04346914Phase 1
- eRAPID: Online Symptom Reporting in Lung CancerCompletedNCT04324437Not applicable
- National Cancer Institute "Cancer Moonshot Biobank"Active, not recruitingNCT04314401
- Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm StudyStatus unknownNCT04314297Phase 2
- Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm StudyStatus unknownNCT04313660Phase 2
- A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung CancerTerminatedNCT04308785Phase 2
- A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USAApproved for marketingNCT04291937
- Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy.CompletedNCT04285866
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid TumorsTerminatedNCT04272034Phase 1
- This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in PatientsStatus unknownNCT04254471Phase 2/3
- A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid TumorsCompletedNCT04247126Phase 1
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid TumorsCompletedNCT04242199Phase 1
- A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)Status unknownNCT04234607Phase 3
- Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung CancerStatus unknownNCT04213937Phase 2
- Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung CancerTerminatedNCT04210037Phase 1/2
- Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung CancerStatus unknownNCT04192682Phase 2/3
- Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLCStatus unknownNCT04189094Phase 2
- LITT and Pembrolizumab in Recurrent Brain MetastasisTerminatedNCT04187872Phase 1
- Prospective Clinicogenomic ProgramCompletedNCT04180176Phase 4
- Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung CancerTerminatedNCT04173325Phase 1
- Mecapegfilgrastim Prevents Neutropenia and Radiation EsophagitisStatus unknownNCT04171986Not applicable
- Watchful Observation of Patients With LD-SCLC Instead of the PCIStatus unknownNCT04168281Not applicable
- Evaluation of AL3818 in Combination With Nivolumab in Solid TumorsActive, not recruitingNCT04165330Phase 1/2